Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice

NCT06983171 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether semaglutide, a medication, can improve liver health in adults with metabolic dysfunction-associated fatty liver disease (MAFLD) by examining changes in liver tissue.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Type Observational

Participants 70 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2025-04 · est. completion 2028-09

Where 1 site · Russia

What this study is testing ClinicalTrials.gov NCT06983171 ↗

Description as written by the study sponsor.

This real-world clinical trial evaluates the effectiveness of semaglutide (target dose is 2.4 mg/week) over 154 weeks (3 years) prescribed to the patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and liver fibrosis (stages 0-4) as a part of routine clinical practice. MAFLD is a common liver condition linked to obesity, type 2 diabetes (T2DM), and metabolic syndrome, which can progress to severe liver damage (cirrhosis) and heart disease. Currently, there are no approved medications for MAFLD, and treatment relies on lifestyle changes. Semaglutide, a GLP-1 receptor agonist, has shown promise in improving liver health and metabolic markers in earlier studies.

Main thing measured	Evaluate the impact of semaglutide therapy on liver morphological changes based on liver histology using the NAFLD Activity Score (NAS).
Sponsor	Center of target therapy
Conditions studied	MAFLD
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06983171 ↗